Last reviewed · How we verify

morphine sulphate in intrasite gel

Institute of Child Health · FDA-approved active Small molecule

Morphine sulphate in intrasite gel delivers the opioid analgesic morphine topically to provide localized pain relief through mu-opioid receptor activation.

Morphine sulphate in intrasite gel delivers the opioid analgesic morphine topically to provide localized pain relief through mu-opioid receptor activation. Used for Localized pain relief in wounds and ulcers, Palliative care pain management.

At a glance

Generic namemorphine sulphate in intrasite gel
SponsorInstitute of Child Health
Drug classOpioid analgesic
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain management
PhaseFDA-approved

Mechanism of action

Morphine is a mu-opioid receptor agonist that binds to opioid receptors in the central and peripheral nervous system to reduce pain perception. When formulated in intrasite gel, a hydrogel vehicle, morphine can be applied directly to wound surfaces or affected areas to provide localized analgesia while maintaining a moist wound environment. This topical delivery approach allows pain relief with potentially reduced systemic absorption compared to parenteral routes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: